Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 608, Issue 2, 2006, Pages 163-168

  Feldmeyer, N ^a   Schmeiser, H H ^a   Muehlbauer, K R ^a   Belharazem, D ^a   Knyazev, Y ^a   Nedelko, T ^a   Hollstein, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Aristolochic acid nephropathy; Carcinogen; Mutational spectra; Senescence

Indexed keywords

ADENINE; AMINO ACID; ARISTOLOCHIC ACID; CARCINOGEN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL IMMORTALIZATION; CODON; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; EMBRYO; FIBROBLAST; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; KIDNEY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR;

ANIMALS; ARISTOLOCHIC ACIDS; BASE SEQUENCE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CODON; DNA; DNA ADDUCTS; DNA MUTATIONAL ANALYSIS; GENES, P53; HUMANS; MICE; MICE, TRANSGENIC; MUTAGENS; POINT MUTATION;

EID: 33748170994     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2006.02.017     Document Type: Article

References (22)

1. Hollstein M., Moeckel G., Hergenhahn M., Spiegelhalder B., Keil M., Werle-Schneider G., Bartsch H., and Brickmann J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res. 405 (1998) 145-154
2. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
3. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
4. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
5. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., and Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20 (2001) 320-328
6. Liu Z., Hergenhahn M., Schmeiser H.H., Wogan G.N., Hong A., and Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U.S.A 101 (2004) 2963-2968
7. Hergenhahn M., Luo J.L., and Hollstein M. p53 Designer genes for the modern mouse. Cell Cycle 3 (2004) 738-741
8. Liu Z., Muehlbauer K.R., Schmeiser H.H., Hergenhahn M., Belharazem D., and Hollstein M.C. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res. 65 (2005) 2583-2587
9. Hainaut P., and Pfeifer G.P. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22 (2001) 367-374
10. Lord G.M., Cook T., Arlt V.M., Schmeiser H.H., Williams G., and Pusey C.D. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358 (2001) 1515-1516
11. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., and Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (2000) 1686-1692
12. Arlt V.M., Stiborova M., and Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002) 265-277
13. Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., and Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43 (2004) e11-e17
14. Kohara A., Suzuki T., Honma M., Ohwada T., and Hayashi M. Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). Mutat. Res. 515 (2002) 63-72
15. Pfau W., Schmeiser H.H., and Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11 (1990) 313-319
16. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15 (1994) 1187-1192
17. Stiborova M., Frei E., Sopko B., Wiessler M., and Schmeiser H.H. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23 (2002) 617-625
18. Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele D.S., and Cosyns J.P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56 (1996) 2025-2028
19. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18 (1997) 1063-1067
20. Hahn W.C., and Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2 (2002) 331-341
21. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., and Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12 (1998) 2424-2433
22. Harvey D.M., and Levine A.J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5 (1991) 2375-2385